Evidence map›Paper›PMID 35904890›Full record

ArticleClinical and experimental dermatology2022

CDKN2A exon 1B deletion predisposing to melanoma and neural system tumour syndrome.

Samantha L Wong, Daniela Martiniuc, Maija Kiuru

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Samantha L WongDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.ORCID https://orcid.org/0000-0001-7703-4434
Daniela MartiniucHereditary Cancer Program, Comprehensive Cancer Center, University of California, Davis, Sacramento, CA, USA.
Maija KiuruDepartment of Dermatology, University of California, Davis, Sacramento, CA, USA.ORCID https://orcid.org/0000-0002-7010-5516

Funding

Molecular basis of melanocytic neviK23AR074530 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KIURU, MAIJA HELENA TUULIA · 2019 to 2023
$840k
NIAMS NIH HHS K23 AR074530NIAMS NIH HHS K23AR074530
6 · The paper itself

Abstract

CDKN2A at chromosome positon 9p21 is a tumour suppressor gene encoding the cell cycle regulators p16 and p14ARF. While melanoma is associated with variants affecting both transcripts, families with mutations involving the p14ARF-specific exon 1B may be predisposed to central nervous system tumours. We describe a family with a deletion of exon 1B in CDKN2A, who had multiple cutaneous melanomas, neural tumours and various malignancies.

Indexed as

MelanomaTumor Suppressor Protein p14ARFAstrocytomaCutaneous Malignant MelanomaCyclin-Dependent Kinase Inhibitor p16ExonsHumansNervous System NeoplasmsPedigreeCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Tumor Suppressor Protein p14ARF

Identifiers

PMID35904890
PMCPMC9712160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.